Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R2R01 in Worsening Heart Failure
NCT06264310Phase 2Completed
- Sponsor
- River 2 Renal Corp
- Start
- Mar 2024
- Primary completion
- Nov 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of R2R01 in heart failure (HF) (4 arms), sponsored by River 2 Renal Corp. Primary endpoint: Treatment-Emergent Adverse Events at 30 days. Started Mar 2024; status: completed.
02
Drugs
R2R01
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06264310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06264310.